Core Insights - Kynam Capital Management reduced its stake in Viridian Therapeutics by 2,957,386 shares in Q4 2025, with an estimated transaction value of $81.11 million based on average pricing [2][4] - The value of Viridian's stake declined by $49.79 million at quarter-end, reflecting both trading and market price effects [2] - Viridian Therapeutics is a clinical-stage biotechnology company focused on developing innovative antibody-based therapies, particularly for thyroid eye disease [6][9] Company Overview - Current stock price of Viridian Therapeutics is $26.98, with a market capitalization of $2.8 billion [4] - The company reported a total revenue of $70.79 million and a net income loss of $342.6 million over the trailing twelve months [4] - Viridian's pipeline includes monoclonal antibody therapies targeting serious diseases, with a focus on thyroid eye disease [9] Financial Performance - Kynam Capital's stake in Viridian now represents 2.92% of its 13F reportable assets under management [8] - Viridian shares have increased by 76% over the past year, significantly outperforming the S&P 500's 15% gain during the same period [8] - The company is facing high research and development costs, nearing $339 million, with a full-year net loss of approximately $343 million [10] Upcoming Milestones - Viridian is approaching a critical period with a PDUFA date for veligrotug on June 30 and multiple Phase 3 readouts for VRDN-003 expected this year [10] - The company has a strong balance sheet with approximately $875 million in cash at year-end, which helps mitigate financial risks [10]

Summary of Viridian Therapeutics Conference Call Company Overview - **Company**: Viridian Therapeutics (NasdaqCM:VRDN) - **Industry**: Biotechnology, specifically focused on treatments for thyroid eye disease (TED) Key Points and Arguments 1. **Lead Program and Upcoming Milestones**: - Viridian's lead program, veligrotug, is expected to go commercial with a PDUFA date of June 30, 2026, following a successful BLA submission in 2025 [2][3] - The TED market is currently valued at $2 billion with only one product available [3] 2. **Clinical Trials and Data**: - Two Phase 3 readouts are anticipated within the next 12 months, one in Q1 and another in Q2 [2][4] - The first Phase 3 trial focuses on the active form of TED, while the second addresses the chronic form [5] 3. **Regulatory Designations**: - The Breakthrough Therapy designation has facilitated positive interactions with the FDA, enhancing the likelihood of priority review for the BLA [9][11] 4. **Market Readiness**: - The company is nearly 100% launch-ready, having built out its field force and market access teams ahead of the PDUFA date [12][14] 5. **Pricing Strategy**: - Pricing discussions with payers indicate potential parity pricing with Tepezza, allowing for a 10%-15% variance [17] - The pricing strategy will consider the full course of treatment, which consists of five infusions compared to Tepezza's eight [18] 6. **Target Patient Population**: - The current TED patient population is skewed towards active cases, but Viridian aims to capture chronic patients with robust clinical data [19][20] - There are approximately 2,000 core prescribers for IGF-1R therapies, providing a focused target for marketing efforts [22] 7. **Market Expansion with Subcutaneous (SubQ) Program**: - The SubQ program (elegrobart) is expected to expand the market by providing a self-administered option, improving access for patients who cannot easily reach infusion centers [45][46] - The anticipated market split in a mature setting is 70% SubQ and 30% IV [49] 8. **Competitive Landscape**: - Several competitors have faced challenges, with notable programs being terminated or showing mixed results [50][52] - Viridian's trials have been well-received, with high enrollment rates indicating strong patient demand [52] 9. **FcRn Portfolio**: - The FcRn portfolio offers strategic optionality, with two compounds in development that could provide differentiated treatment options in the future [54][55] 10. **TSHR-targeted Program**: - A new TSHR antibody program is in preclinical stages, with potential applications in both TED and Graves' disease [59][60] Additional Important Information - The company has successfully enrolled a significant number of patients in clinical trials, indicating strong interest and demand for IGF-1R therapies [52] - The competitive landscape has shifted favorably for Viridian, with fewer viable competitors in the TED space [53] - The company plans to file an IND for the TSHR program in Q4 2026, indicating ongoing innovation and development [60][64]

Core Insights - Viridian Therapeutics, Inc. (NASDAQ:VRDN) is recognized as one of the 10 Fastest Growing NASDAQ Stocks to Buy [1] - The company is preparing for a potential commercial launch of its treatment for thyroid eye disease in mid-2026, contingent on regulatory approval [2] - Recent earnings reports indicate a Q4 EPS of ($1.08), which was below the consensus estimate of ($1.00), and Q4 revenue of $132,000, significantly lower than the consensus of $15.75 million [4] Price Target Adjustments - RBC Capital has lowered its price target for Viridian Therapeutics to $42 from $45 while maintaining an Outperform rating, citing the company's positioning for a transition to commercial operations in 2026 [2] - Jefferies has raised its price target to $45 from $44, affirming a Buy rating, and noted that all key events are on track, with a focus on upcoming Phase 3 trial results [3] Company Developments - The company is advancing its pipeline with the BLA filing for veligrotug under Priority Review and a PDUFA target date set for June 30, 2026 [4] - The submission of the MAA to the EMA is aimed at expanding the global market opportunity for veligrotug [4] - Upcoming topline data for elegrobart from the REVEAL-1 trial is expected next month, which is crucial for establishing both veligrotug and elegrobart as foundational therapies for thyroid eye disease [4]

Summary of Viridian Therapeutics Conference Call Company Overview - **Company**: Viridian Therapeutics - **Participants**: - Stephen Mahoney - CEO - Shan Wu - CBO - Tony Casciano - CCO - **Conference**: TD Cowen's 46th Annual Healthcare Conference Key Points Industry and Market Insights - The Thyroid Eye Disease (TED) market in the U.S. has approximately 500,000 patients, with around 200,000 classified as moderate to severe and about 150,000 under physician care [doc id='22'] - Current treatment with TEPEZZA sees about 7,000 patients treated annually, indicating low single-digit market penetration [doc id='22'] - The company believes there is significant unmet need and opportunity to help more patients due to the burdensome treatment regimen of existing therapies [doc id='22'][doc id='23'] Product Development and Pipeline - **Veli (veligrotug)**: - Received Breakthrough Therapy designation and priority review from the FDA, with a PDUFA date set for June 30 [doc id='4'][doc id='11] - Phase 3 trials showed rapid onset of treatment effects, with significant improvements in diplopia (double vision) resolution [doc id='8'][doc id='9] - Treatment regimen involves 5 infusions at 10 mg/kg, compared to competitors' 8 infusions at 20 mg/kg, which is expected to appeal to patients and physicians [doc id='12][doc id='10] - **FcRn Programs**: - Two programs, VRDN-006 and VRDN-008, are in development, focusing on IgG suppression and albumin-sparing effects [doc id='5'][doc id='6] - Data from VRDN-008 is expected in the second half of the year, which will inform future development decisions [doc id='56] - **TSHR Program**: - A new program targeting the TSH receptor, which is believed to complement existing TED treatments and has potential applications in Graves' disease [doc id='58'][doc id='59] Commercial Strategy - The company plans to launch with a sales force of under 100 representatives, leveraging the existing market established by TEPEZZA [doc id='26'][doc id='27] - The strategy includes targeting all prescribers of TEPEZZA, which is estimated to be around 2,000 core prescribers [doc id='27] - The company aims to differentiate itself by offering a simpler and faster treatment option, which is expected to improve patient compliance and market penetration [doc id='12][doc id='23] Regulatory and Competitive Landscape - Consistent communication with the FDA has been maintained, which is viewed positively by the company [doc id='17'][doc id='18] - The competitive landscape is acknowledged, with a focus on differentiating Veli from existing therapies through its dosing regimen and efficacy [doc id='10][doc id='12] Future Outlook - The company is optimistic about the upcoming data readouts and believes that the clinical trial designs will effectively control for placebo effects [doc id='47][doc id='48] - There is a focus on expanding treatment options for TED and potentially addressing the chronic population, which may have different treatment urgencies [doc id='32][doc id='35] Additional Considerations - The company is exploring international opportunities, particularly in Europe and Japan, where there is a significant unmet need for TED treatments [doc id='36][doc id='40] - Pricing strategies in international markets remain a key consideration as the company prepares for potential launches [doc id='36] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting the company's focus on innovation in the TED market and its commitment to addressing patient needs through differentiated therapies.

分组1 - Viridian Therapeutics reported a quarterly loss of $1.08 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.90, and compared to a loss of $0.81 per share a year ago, indicating an earnings surprise of -20.67% [1] - The company posted revenues of $0.13 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 99.29%, and this was an increase from revenues of $0.07 million a year ago [2] - The stock has underperformed the market, losing about 7% since the beginning of the year, while the S&P 500 gained 1.5% [3] 分组2 - The earnings outlook for Viridian Therapeutics is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Viridian Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.98 on $0.1 million in revenues, and for the current fiscal year, it is -$3.50 on $88.07 million in revenues [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Viridian Therapeutics belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8]

Financial Performance - The company reported net losses of $342.6 million and $269.9 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $1,338.5 million as of December 31, 2025[255]. - As of December 31, 2025, the company had $874.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least twelve months[262]. - The company anticipates significant operating losses to continue as it advances product candidates through clinical trials and develops new candidates[260]. - The company has never generated revenue from product sales and does not expect to do so until product candidates receive marketing authorization[268]. - The company may need to secure additional capital to fund operations, which could involve selling equity or entering strategic collaborations[264]. Product Development and Regulatory Approval - The company entered into a Purchase and Sale Agreement with DRI, receiving $55 million at signing and having the potential for up to $245 million in milestone payments, contingent on clinical trial and regulatory approval conditions[278]. - Future revenue will depend on the successful commercialization of product candidates and the establishment of a commercial supply chain[259]. - The THRIVE and THRIVE-2 phase 3 clinical trials are expected to support global health authority registration for veligrotug, with a safety database comprising at least 300 treated patients[280]. - A global pivotal program for elegrobart is underway, with REVEAL-1 and REVEAL-2 phase 3 clinical trials also targeting a safety database of at least 300 treated patients[280]. - Regulatory authorities may require additional patients in the safety database or other steps, potentially delaying the marketing approval process for both veligrotug and elegrobart[280]. - The FDA's target action date for the BLA submission for veligrotug is June 30, 2026, but delays could impact this timeline[291]. - The company submitted a Marketing Authorization Application (MAA) to the EMA in January 2026 for veligrotug, seeking regulatory approval in Europe[292]. - Regulatory approval processes are lengthy and can vary significantly, potentially impacting the commercialization timeline for product candidates[293]. - The company may need to conduct additional clinical or nonclinical studies if manufacturing or formulation changes are made, which could increase development costs[283]. - Ongoing regulatory requirements will apply post-approval, including compliance with manufacturing, labeling, and safety reporting standards[284]. Risks and Challenges - The company faces risks related to its ability to raise capital on favorable terms, which could impact its financial condition and operational plans[257]. - Business disruptions could adversely affect the company's operations and financial condition, increasing costs and expenses[277]. - The company may need to delay or reduce product development efforts if it cannot secure additional funding[276]. - The company faces substantial uncertainty regarding the potential impacts of a prolonged U.S. federal government shutdown on its business, particularly concerning the FDA's operations and regulatory approvals[297]. - Regulatory authorities may approve product candidates for fewer indications or more limited patient populations than requested, which could materially harm commercial prospects[295]. Competition and Market Dynamics - The company faces significant competition from major pharmaceutical and biotechnology firms, which may develop or commercialize products faster, impacting the market position of its candidates[332]. - If competitors obtain marketing approval more rapidly, they could establish a strong market presence before the company can enter the market[335]. - The commercial success of the company’s products will depend on market adoption by patients, payors, and healthcare providers, which is uncertain[337]. - The company must demonstrate the clinical efficacy and safety of its products to gain acceptance among clinicians and payors[339]. - The company’s product candidates may have inferior efficacy and safety profiles compared to competitors, potentially affecting their marketability[333]. Intellectual Property and Legal Risks - The company relies on patent rights and trade secrets for intellectual property protection, which may not be sufficient to compete effectively in the market[378]. - The patent position is uncertain, and challenges to patent validity could impair the company's ability to prevent competition[380]. - The company has filed patent applications covering various aspects of its product candidates, but cannot assure the issuance or enforceability of these patents[381]. - The company may not have sufficient patent term protections, as patents generally expire 20 years after filing, potentially exposing it to competition[383]. - Changes in patent laws and recent reforms could increase uncertainties and costs surrounding patent prosecution and enforcement, impacting the company's business[386]. Compliance and Regulatory Environment - The company is subject to various obligations under intellectual property licenses, and failure to comply could result in loss of important license rights[407]. - Non-compliance with regulatory requirements could lead to significant penalties, including fines and withdrawal of approvals, adversely affecting the company's operations[429]. - The company must comply with complex pricing and reporting obligations, and any inaccuracies could lead to penalties that materially affect its financial condition[437]. - Non-compliance with U.S. and foreign data protection laws could result in civil or criminal penalties, fines, or sanctions, negatively affecting the company's operating results and business[442]. Human Resources and Management - The company is highly dependent on its management team, and the loss of key personnel could delay the development of product candidates and harm business operations[447]. - Competition for skilled personnel in the biotechnology and pharmaceutical industries is intense, which may limit the company's ability to hire and retain qualified employees[449]. - The company utilizes shares under its Amended and Restated 2016 Equity Incentive Plan to attract and retain talent, and failure to secure stockholder approval for share increases may adversely affect talent acquisition[451].

Financial Performance - The company reported a cash position of $875 million as of December 31, 2025, up from $717.6 million in 2024, indicating strong financial health[6] - The net loss for the year ended December 31, 2025, was $342.6 million, compared to a net loss of $269.9 million in 2024[6] - Total revenue for the three months ended December 31, 2025, was $132,000, compared to $72,000 for the same period in 2024, representing an increase of 83.33%[17] - License revenue for the year ended December 31, 2025, was $70,000, while there was no license revenue reported for 2024[17] - Net loss for the three months ended December 31, 2025, was $120,355, compared to a net loss of $79,725 for the same period in 2024, an increase of 50.93%[17] - Net loss per share for common stock for the year ended December 31, 2025, was $(3.32), compared to $(3.07) in 2024, indicating a decline in performance[17] - The weighted-average common shares outstanding for the year ended December 31, 2025, were 84,803,355, compared to 67,885,831 in 2024, an increase of 24.93%[17] Research and Development - Research and development expenses increased to $338.9 million for the year ended December 31, 2025, compared to $238.3 million in 2024, driven by ongoing clinical trials and manufacturing activities[6] - Research and development expenses for the three months ended December 31, 2025, were $89,208, up from $71,960 in 2024, indicating a 24% increase[17] - Viridian is advancing VRDN-008 into a phase 1 clinical trial, with data expected in the second half of 2026[6] - The company anticipates reporting topline data for elegrobart (VRDN-003) from the REVEAL-1 study in Q1 2026 and from the REVEAL-2 study in Q2 2026[6] Expenses - Selling, general and administrative expenses rose to $95.3 million in 2025 from $61.1 million in 2024, reflecting preparatory activities for veligrotug[6] - Selling, general and administrative expenses for the three months ended December 31, 2025, were $33,673, compared to $15,584 in 2024, reflecting a 115% increase[17] Assets and Liabilities - Total assets as of December 31, 2025, were $899,418, up from $742,403 as of December 31, 2024, representing a growth of 21.14%[19] - Total liabilities increased to $177,251 as of December 31, 2025, from $70,764 in 2024, marking a significant rise of 150.00%[19] - Total stockholders' equity as of December 31, 2025, was $722,167, compared to $671,639 in 2024, showing an increase of 7.51%[19] Regulatory and Market Developments - Veligrotug's PDUFA target action date is set for June 30, 2026, with U.S. commercial preparations on track for a mid-2026 launch if approved[1] - Veligrotug received Breakthrough Therapy designation from the FDA in 2025, supporting its clinical profile in treating thyroid eye disease (TED)[3] - The MAA for veligrotug was submitted to the EMA in January 2026, aligning with the company's global strategy[3] - The company expects to fund its current business plans through profitability based on existing cash and anticipated revenues from veligrotug and elegrobart, if approved[6]

Core Insights - Viridian Therapeutics, Inc. reported its business highlights and financial results for Q4 and the full year ended December 31, 2025, indicating a strong performance and strategic execution as it enters 2026 [1] Business Highlights - The company is focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases [1] - CEO Steve Mahoney emphasized the momentum gained from continued execution in their business strategy [1]

Company Overview - Viridian Therapeutics is a clinical-stage biotechnology company focused on developing innovative antibody-based therapies, particularly for thyroid eye disease [6] - The company utilizes monoclonal antibody engineering to advance its pipeline and address unmet medical needs in rare disorders [6] - As of February 17, 2026, Viridian's market capitalization is $2.30 billion, with a revenue of $70.79 million and a net income of -$301.97 million [4] Recent Developments - On February 17, 2026, Commodore Capital disclosed the sale of its entire 3,200,000-share position in Viridian Therapeutics, amounting to approximately $69.06 million [1][2] - This liquidation reduced Viridian's weighting in Commodore's portfolio from 3.4% to zero [7] - Following the sale, Viridian's shares were priced at $28.29, reflecting a 75% increase over the past year, outperforming the S&P 500 [7][10] Future Prospects - Viridian is entering 2026 with significant potential catalysts, including the FDA's acceptance of veligrotug's BLA for thyroid eye disease, with a PDUFA date set for June 30 [10] - The company has approximately $888 million in cash and investments, indicating a strong financial position to fund operations until profitability [10] - The removal of Commodore's stake may suggest a strategic shift towards other investments or a response to valuation considerations, as Viridian approaches a catalyst-heavy year [11]

Core Insights - Viridian Metals Inc. has reported final assay results from 17 drill holes completed during its 2025 drilling program at the Kraken Main Zone, confirming significant near-surface sulphide mineralization [1][6][10] Drilling Results - The final assays indicate consistent near-surface sulphide mineralization, extending confirmed mineralization north by 360 meters, with tens of meters of mineralization intersected above the primary target horizon [4][6] - Near-continuous sulphide mineralization has been defined over an area of approximately 600 meters by 200 meters, representing less than 10% of the interpreted 5 km Main Zone [6][11] - Drilling has consistently intersected sulphide mineralization within the lower Michikamau Intrusion and along its basal contact, suggesting a vertically extensive mineralized system [9][10] Future Plans - Planning for an expanded 2026 drilling program is underway, which will include step-outs along the 5-kilometer Main Zone Conductor and deeper holes beneath the strongest conductivity responses [12] Company Overview - Viridian Metals is focused on generative metal exploration with an emphasis on environmental responsibility and ethical practices, primarily targeting copper, nickel, and cobalt [25]